The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...
With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...
Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.
Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
And patients taking any dose of the dual GLP-1/GIP receptor agonist had improvements in blood glucose, lipids, blood pressure ...
The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...
Medications like Ozempic and Wegovy are famous for their weight loss benefits, but some scientists want to know more about how these drugs impact muscle loss.
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?
I already knew that chia seeds were highly nutritious—and chock-full of essential nutrients like fiber and protein—but I didn ...